Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
- Associated Therapies
- -
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2478
- Registration Number
- NCT04513717
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Wonju Severance Christian Hospital
- Target Recruit Count
- 164
- Registration Number
- NCT04248621
- Locations
- 🇰🇷
Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of
🇰🇷Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of
🇰🇷Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 979
- Registration Number
- NCT04034095
- Locations
- 🇯🇵
Akita University Hospital, Akita, Japan
🇯🇵Juntendo University Hospital, Bunkyo Ku, Japan
🇯🇵Tokyo Medical and Dental University Hospital, Bunkyo Ku, Japan
INTREPId (INTermediate Risk Erection PreservatIon Trial)
- Conditions
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 234
- Registration Number
- NCT04025372
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women Hospital, Boston, Massachusetts, United States
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- RTOG Foundation, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT03809000
- Locations
- 🇺🇸
USC Medical Center - Los Angeles County, Los Angeles, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Sutter Roseville Medical Center, Roseville, California, United States
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Conditions
- Interventions
- Drug: AbirateroneDrug: BicalutamideDrug: DegarelixDrug: FlutamideDrug: DocetaxelDrug: Goserelin AcetateDrug: Histrelin AcetateDrug: Leuprolide AcetateDrug: NilutamideProcedure: OrchiectomyOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: PrednisoneProcedure: Radical ProstatectomyDrug: Triptorelin
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1273
- Registration Number
- NCT03678025
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 30
- Registration Number
- NCT03650894
- Locations
- 🇺🇸
Providence Oncology & Hematology Care Clinic - Eastside, Portland, Oregon, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03541928
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 654
- Registration Number
- NCT03520478
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇧🇬Complex oncological center - Bourgas, Burgas, Bulgaria
🇧🇬MHAT - Dobrich. AD, Dobrich, Bulgaria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.